US equities |
SPCX $167.66 ▲+5.47% NVDA $237.15 ▲+1.37% MU $1,065.45 ▼-0.88% TSLA $378.04 ▲+2.01% MSFT $525.34 ▲+1.51% SNDK $1,708.51 ▼-0.67% INTC $116.99 ▼-1.96% META $743.93 ▲+2.18%
FinancialContent

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

24.04 -1.54 (-6.00%)
Delayed Quote Updated: 1:01 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For Cue Biopharma ↗
 
Via Benzinga
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Cue Biopharma Announces Proposed Public Offering
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024 ↗
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket ↗
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
News headline image
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 ↗
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 ↗
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >